About this episode
A cardiologist in Nagpur performs two similar angioplasties. But the stents inside his patients tell two very different stories. One gets Indian-made devices under a government scheme. The other insists on an imported brand.
This contrast is now common across India. Price caps pushed foreign stent makers into a corner in 2017. But they never left.
And now, they’re back with new valves, pacemakers, and high-margin cardiac devices. Domestic players, meanwhile, grew fast but still struggle with data, technology, and trust.
Tune in.
Daybreak is produced from the newsroom of The Ken, India’s first subscriber-only business news platform. Subscribe for more exclusive, deeply-reported, and analytical business stories.
Get every episode summarized
Each time Daybreak publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Daybreak
Uber knocks at a new door as Rapido shuts many others
Daybreak
Akasa Air has the best seat in Indian aviation. It just can't find a place to pa...
Daybreak
A social media ban for under-16s is Big Tech's get-out-of-jail-free card. Here's...
Daybreak
Owning a home makes you feel rich. Owning an office could actually make you rich
Daybreak